Teladoc Health, Inc. (TDOC)
NYSE: TDOC · Real-Time Price · USD
5.10
-0.06 (-1.16%)
At close: Mar 3, 2026, 4:00 PM EST
5.07
-0.03 (-0.59%)
After-hours: Mar 3, 2026, 7:14 PM EST
Teladoc Health Stock Forecast
Stock Price Forecast
The 15 analysts that cover Teladoc Health stock have a consensus rating of "Hold" and an average price target of $7.40, which forecasts a 45.10% increase in the stock price over the next year. The lowest target is $5.00 and the highest is $10.
Price Target: $7.40 (+45.10%)
Analyst Consensus: Hold
Analyst Ratings
The average analyst rating for Teladoc Health stock is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 4 | 2 | 2 | 2 | 1 | 2 |
| Hold | 11 | 10 | 10 | 10 | 12 | 12 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 17 | 14 | 14 | 14 | 15 | 16 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Citigroup | Citigroup | Hold Maintains $9 → $6 | Hold | Maintains | $9 → $6 | +17.65% | Mar 3, 2026 |
| Oppenheimer | Oppenheimer | Buy Maintains $12 → $7 | Buy | Maintains | $12 → $7 | +37.25% | Mar 3, 2026 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $12 → $10 | Strong Buy | Maintains | $12 → $10 | +96.08% | Feb 26, 2026 |
| Leerink Partners | Leerink Partners | Hold Maintains $8.5 → $5.5 | Hold | Maintains | $8.5 → $5.5 | +7.84% | Feb 26, 2026 |
| TD Cowen | TD Cowen | Hold Maintains $8 → $6 | Hold | Maintains | $8 → $6 | +17.65% | Feb 26, 2026 |
Financial Forecast
Revenue This Year
2.57B
from 2.53B
Increased by 1.74%
Revenue Next Year
2.61B
from 2.57B
Increased by 1.24%
EPS This Year
-0.88
from -1.14
EPS Next Year
-0.76
from -0.88
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 2.7B | 2.8B | |||
| Avg | 2.6B | 2.6B | |||
| Low | 2.4B | 2.4B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 7.9% | 8.5% | |||
| Avg | 1.7% | 1.2% | |||
| Low | -4.1% | -5.7% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -0.45 | -0.43 | |||
| Avg | -0.88 | -0.76 | |||
| Low | -1.25 | -1.19 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.